PODD INSULET CORP
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1145197 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY26.5%
TTM net income YoY74.2%
TTM EPS YoY78.4%
Revenue 3-yr CAGR27.0%
Net income 3-yr CAGR52.9%
Margins
Gross margin71.9%
Operating margin18.4%
Net margin13.4%
FCF margin8.2%
EBITDA margin21.7%
Returns
ROE28.9%
ROA13.3%
ROIC (approx.)25.5%
Asset turnover0.99x
Leverage & solvency
Liabilities / assets53.8%
Debt / equity0.61x
Current ratio2.51x
Interest coverage9.91x
Cash quality & payout
Operating cash flow / net income1.19x
Accruals ratio-2.5%
Payout ratio—
Capex / revenue7.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.71B | $2.07B |
| Cost of revenue | $768.20M | $625.90M |
| Gross profit | $1.94B | $1.45B |
| R&D expense | $301.10M | $219.60M |
| SG&A expense | $1.17B | $917.20M |
| Operating income | $473.80M | $308.90M |
| Interest expense | $59.40M | $42.70M |
| Pretax income | $339.50M | $300.20M |
| Income tax | $92.40M | -$118.10M |
| Net income | $247.10M | $418.30M |
| EBITDA | $564.20M | $389.70M |
| EPS (basic) | 3.51 | 5.97 |
| EPS (diluted) | 3.48 | 5.78 |
| Weighted avg. shares (diluted) | 71.89M | 73.89M |
| Balance sheet | ||
| Cash & equivalents | $716.10M | $953.40M |
| Receivables | $516.90M | — |
| Inventory | $452.60M | $430.40M |
| Current assets | $1.91B | $1.89B |
| PP&E, net | $819.50M | $723.10M |
| Goodwill | $51.60M | $51.50M |
| Intangibles | $117.10M | $98.50M |
| Total assets | $3.19B | $3.09B |
| Current liabilities | $680.10M | $528.40M |
| Short-term debt | $18.40M | $83.80M |
| Long-term debt | $930.80M | $1.30B |
| Total debt | $949.20M | $1.38B |
| Total liabilities | $1.68B | $1.88B |
| Shareholders' equity | $1.52B | $1.21B |
| Net debt | $233.10M | $426.50M |
| Shares outstanding | 70.39M | 70.20M |
| Cash flow statement | ||
| Operating cash flow | $569.30M | $430.20M |
| Capital expenditure | $191.60M | $124.90M |
| Free cash flow | $377.70M | $305.30M |
| Investing cash flow | -$222.70M | -$146.20M |
| Financing cash flow | -$595.30M | -$28.00M |
| Depreciation & amortization | $90.40M | $80.80M |
| Stock-based compensation | $62.70M | $69.30M |
| Share buybacks | $59.60M | $0 |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.